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(v) Abstract 13 
The vascular changes associated with endometrial maturation in preparation for embryo 14 
implantation depend on numerous growth factors, known to regulate key angiogenic events. 15 
Primarily, the vascular endothelial growth factor (VEGF) family promotes vascular growth, 16 
whilst the angiopoietins maintain blood vessel integrity. The aim was to analyse protein levels 17 
of VEGFA ligand and receptors, Angiopoietin-1 and 2 (ANG1/2) and endothelial cell receptor 18 
tyrosine kinase (TIE2) in the ovine endometrium in the follicular and luteal phases of the 19 
oestrus cycle and in response to ovarian steroids.  VEGFA and its receptors were localised in 20 
both vascular cells and non-vascular epithelium (glandular and luminal epithelium) and 21 
stroma cells.  VEGFA and VEGFR2 protein were elevated in vascular cells in follicular phase 22 
endometrium, compared to luteal phase, most significantly in response to oestradiol.  VEGFR1 23 
was expressed by epithelial cells, endothelial cells, and was stimulated in response to 24 
oestradiol.  In contrast, Ang-1 and Ang-2 proteins were elevated in luteal phase endometrium 25 
compared to follicular phase, and in response to progesterone, evident in vascular smooth 26 
muscle cells and glands which surround TIE2-expressing blood vessels. Our findings indicate 27 
that VEGFA is stimulated by oestradiol, most predominantly in follicular phase endometrium, 28 
and Ang-1 and 2 are stimulated by progesterone and were increased during the luteal phase 29 
of the oestrus cycle, during the time of vascular maturation. 30 
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 (vi) Introduction 32 
Throughout the oestrus cycle, continuous growth and regeneration of the endometrium is 33 
essential in providing a healthy maternal environment for the establishment of pregnancy 34 
(Sagsoz et al. 2011). Cyclical, morphological changes in the endometrium are accompanied by 35 
extensive remodeling of the vasculature to produce a receptive, vascularised environment 36 
(Torry et al. 2007, Ma et al. 2001).  Such vascular remodeling is dependent on hormonally 37 
regulated angiogenesis (Walter et al. 2010).  Under the influence of oestradiol, the follicular 38 
phase is associated with vascular growth, with rapid proliferation of endothelial cells 39 
(Boroujeni et al. 2016, Heryanto and Rogers 2002).  As the vascular bed expands, angiogenic 40 
processes ensure stabilisation and maturation of vessels into the luteal phase of the cycle 41 
(Girling and Rogers 2009, Matsumoto et al. 2002), when progesterone is the dominant 42 
hormone.  These cyclical changes in the ovarian steroids have been shown to correlate with 43 
the expression of angiogenic factors in the endometrium, essential to coordinate specific 44 
angiogenic events. 45 
Angiogenic processes, including endothelial cell (EC) proliferation, migration and vessel 46 
formation, not only depend on the coordinate actions of oestradiol and progesterone, but 47 
interactions with several angiogenic growth factors (Meduri et al. 2000).  Vascular Endothelial 48 
Growth Factor (VEGF) is a potent angiogenic mitogen for endothelial cells, which can also 49 
promote vascular permeability (Tasaki et al. 2010), by variable interactions with its receptors 50 
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1; Flt-1) and Vascular Endothelial 51 
Growth Factor Receptor 2 (VEGFR2; KDR) (Fan et al. 2008). The mitogenic effect of VEGF on 52 
EC proliferation is known to be transduced via VEGFR2 (Thomas 1996), however, the exact 53 
role of VEGFR1 in the endometrium remains elusive. Although VEGFR1-mediated signalling is 54 
essential for vascularization, the higher binding affinity of VEGF for VEGFR1, only elicits a weak 55 
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angiogenic signal that does not stimulate endothelial cell proliferation (Tasaki et al. 2010).  56 
Furthermore, a non-vascular function for VEGF is proposed, as it is evident that the primary 57 
cellular source of VEGF in the uterus is the endometrial epithelium (Girling and Rogers 2009).  58 
This observation supports a non-angiogenic role for VEGF in epithelial cell function, in addition 59 
to a pro-angiogenic paracrine mechanism for VEGF.   60 
Several groups have examined VEGF and receptors in pregnant and non-pregnant uterus and 61 
found cycle-dependent expression in rabbits (Das et al. 1997), pig (Winther et al. 1999), 62 
humans (Moller et al. 2001), marmosets (Rowe et al. 2003) and cows (Sagsoz and Saruhan 63 
2011).  Most studies show that oestradiol elicits its tropic effects on uterine angiogenesis by 64 
elevated expression and activity of VEGF. The first clear demonstration of oestradiol-induced 65 
effect of VEGF was from a study in the rat uterus, in which VEGF expression increased in 66 
response to oestradiol treatment (Cullinan-Bove and Koos 1993). Further studies by the same 67 
group went on to show the mechanism by which oestradiol stimulated VEGF expression 68 
resulting in increased microvascular permeability, in both isolated uterine epithelial cells and 69 
whole rat uteri (Kazi et al. 2009), (Kazi and Koos 2007). This effect was dependent on the 70 
simultaneous recruitment of hypoxia-inducible factor and (HIF1) and estrogen receptor alpha 71 
(ESR1) to the VEGFA gene promoter. Oestradiol enhanced VEGF in endometrial cells of mice 72 
(Shweiki et al. 1993), Baboons (Niklaus et al. 2003), rhesus macaques (Nayak and Brenner 73 
2002) and humans (Mueller et al. 2000), with less known about the response of VEGF to 74 
progesterone. 75 
Far less is known about another key group of angiogenic growth regulators, the angiopoietins, 76 
in the endometrium.  Both angiopoietin-1 and 2 (Ang-1/2) act via EC tyrosine kinase receptor 77 
(TIE-2), and have opposing roles depending on the availability and interactions with VEGF 78 
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(Hirchenhain et al. 2003).  Ang-1 is an agonist of TIE-2, which promotes interactions between 79 
endothelial cells and vascular smooth muscle cells, thereby contributing to the structural 80 
integrity and stabilisation of a newly formed vascular network (Tsuzuki et al. 2013).    In 81 
contrast, Ang-2 is a natural antagonist of Ang-1 activity, competing at receptor binding sites, 82 
and its opposing functions are dependent on the presence of VEGF (Guo et al. 2012a).  83 
A small number of studies report on the angiopoietins in the endometrium and are limited to 84 
humans and mice (Tsuzuki et al. 2013, Guo et al. 2012b).  In human endometrium, 85 
immunoreactivity for Ang-1 was strongest in the glands with weaker staining in vascular 86 
smooth muscle cells (VSMCs) and ECs, throughout the menstrual cycle (Lash et al. 2012). 87 
Whereas, Ang-2 increased in the mid-late secretory phase, compared with early secretory or 88 
follicular phase. In early pregnant mouse uterus, Ang-2 and 3 increased by day 5 in response 89 
to the ovarian steroids, and were implicated in processes of decidualization (Guo et al. 2012a).  90 
No previous studies report on the expression of the angiopoietins in the cyclic ovine uterus, 91 
although one study showed increasing Ang-1 and 2 mRNA levels with the progression of early 92 
stage pregnancy in ovine maternal placenta (Grazul-Bilska et al. 2010).  Another study 93 
investigated the effects of oestradiol regulation on several angiogenic growth factors in the 94 
endometrium, using an ovariectomised ewe model (Johnson et al. 2006).  An increase in Ang-95 
1, Ang-2 and TIE-2 mRNA expression in the endometrium was shown two hours post-96 
oestradiol treatment. However, the importance of further study to clarify the expression and 97 
potential functions of the angiopoietins in the endometrium is essential.  98 
Although a previous study reported on VEGF in ovine caruncular tissue during later pregnancy 99 
(Ruiz-Gonzalez et al. 2013), there is a distinct lack of knowledge regarding the localisation of 100 
VEGF family and the angiopoietins in the ovine endometrium and their regulation by steroid 101 
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hormones.  Thus, the aim of the present study was to identify the temporal and spatial 102 
distribution patterns of VEGF and receptors and the angiopoietin family in the cyclic ovine 103 
endometrium, and in response to the ovarian steroids. Defining the expression pattern of 104 
these factors may provide further evidence to elucidate their physiological functions in the 105 
ovine uterus. To the best of our knowledge this is the first study, which thoroughly explored 106 
and demonstrated VEGF/receptors and ANG1/2 and TIE2 expression in both follicular and 107 
luteal phases of the oestrous cycle in the sheep model.  108 
 
Materials and Methods 109 
Animals and Tissue Collection 110 
All experimental procedures complied with regulations in the UK Animal (Scientific 111 
Procedures) Act, 1986 and were approved by the College’s Ethics and Welfare Committee.  112 
Thirty, proven fertile non-pregnant Welsh mountain ewes were used in this study, housed 113 
indoors and fed with hay and concentrate diet. Eight ewes were synchronized to a common 114 
day of oestrus using intravaginal Chronogest sponge (Intervet UK Ltd, Cambridge, UK) for 11 115 
days and treated with 200 IU Pregnant Mare’s Serum Gonadotrophin (PMSG; Intervet UK, Ltd, 116 
Buckinghamshire, UK) intramuscularly at the time of sponge removal.  Having observed 117 
oestrous 24 h following sponge removal, reproductive tracts were collected following 118 
euthanasia on days 9 for luteal phase (n=5) and days 16 for follicular phase (n=3).  Blood 119 
samples were also collected from intact ewes at the time of killing. The remaining 22 animals 120 
were ovariectomised as previously described by (Raheem et al. 2013).  To remove the effect 121 
of endogenous gonadotrophins, luteinising hormone and follicle stimulating hormone (LH and 122 
FSH), ewes were administered Buserelin acetate (gonadotrophin agonist; Surefact, Aventis 123 
Pharma Ltd, Kent, UK) continuously by an osmotic pump (ALZET model, DURECT Corp, 124 
7 
 
Cupertino, US), inserted subcutaneously in the forelimb at the time of ovariectomy.  Buserelin 125 
was administered at 2mg in 2 ml normal saline and pumps were designed to secrete 2.5µl/h 126 
for 28 days.  Following an 8-day recovery period, ovariectomised ewes were randomly 127 
assigned to receive daily intramuscular injections of one of the three treatments: i) 2ml corn 128 
oil alone (also used as a vehicle for the hormonal treatments) for 10 days (ovariectomised; 129 
OVX; n=6), ii) 25 mg progesterone for ten consecutive days (ovariectomised progesterone 130 
treated; OVX P; n=8), or iii) 6 µg of 17β-oestradiol and 25 mg progesterone for 3 days followed 131 
by progesterone only (25 mg) for the remaining 7 days (ovariectomised estradiol + 132 
progesterone treated; OVX EP; n=8).  Blood samples were collected on alternate days 133 
following the first day of treatment; plasma was separated and stored at -20oC until hormone 134 
assays were performed for progesterone and oestradiol.  Animals were euthanized 24 h after 135 
the last hormone injection was administered and uterine horns were collected and several 136 
dissected transverse sections were fixed in 4% formalin (BDH, Poole, UK), stored in 70% 137 
ethanol and later embedded in paraffin wax blocks for immunohistochemistry.   138 
Measurements of oestradiol and progesterone levels in plasma 139 
Progesterone plasma concentrations were analysed using ELISA kits (Ridgeway Science, 140 
Cirencester, UK) according to manufacturer’s instructions using standards prepared in 141 
charcoal-stripped sheep plasma ranging from 0.5 to 20 ng/ml. Oestradiol plasma 142 
concentrations were determined by RIA as previously described (Robinson et al. 2002).  The 143 
intra-assay coefficient of variation was 3.2%.  The inter-assay coefficient of variation was not 144 
calculated as all samples were analysed in a single assay. 145 
Immunohistochemistry 146 
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Formalin fixed paraffin wax embedded sections (5µm) of uterine tissue from each treatment 147 
group were mounted on superfrost slides (VWR International Co, Leicestershire, UK), 148 
dewaxed in histoclear (National Diagnostics, UK) and rehydrated through a descending series 149 
of alcohols.  Antigen retrieval for unmasking epitopes was performed by microwave boiling in 150 
0.01 M sodium citrate buffer (pH 6.0) for 20 min.  Slides were rinsed in PBS (phosphate 151 
buffered saline; 1X, pH 7) and endogenous peroxidase activity was inactivated in 3% (v/v) 152 
hydrogen peroxide in methanol for 20 min.  Following further PBS washes, non-specific 153 
protein binding was blocked in PBS buffer containing 10% (v/v) goat serum (Dako, Glostrup, 154 
Denmark) + 4% (w/v) BSA for 60 min in a humidified chamber.  Slides were incubated with 155 
primary antibodies against VEGFA (polyclonal rabbit anti-human VEGF; 1:300), VEGFR1 156 
(polyclonal rabbit anti-human VEGFR1; 1:300), VEGFR2 (polyclonal rabbit anti-mouse 157 
VEGFR2; 1:50), ANG1 (polyclonal rabbit Ang-1; 1: 50), ANG2 (polyclonal rabbit anti-human 158 
Ang2; 1:100), Tie-2 (polyclonal rabbit anti-human Tie-2; 1:100), all purchased from Santa Cruz, 159 
Inc, Biotechnology, Inc, Santa Cruz, CA, USA) diluted in PBS, overnight at 4oC in a humidified 160 
chamber.  Negative control slides were treated in the same manner except the replacement 161 
of rabbit IgG diluted in PBS in the absence of primary antibody.  On the following day, slides 162 
were rinsed in PBS and incubated with the secondary antibody biotinylated goat anti-rabbit 163 
(1:200, Dako) for 60 min at room temperature in a humidified chamber.  Slides were rinsed 164 
prior to application of the avidin-biotin complex solution (Vectastain Universal Elite ABC kit, 165 
Vector Laboratories, Peterborough, UK) for 30 min at room temperature and detection of the 166 
primary antibody was visualised using 3, 3’-Diaminobenzidine (DAB; Dako, Glostrup, 167 
Denmark) until colour development.  Slides were counterstained in Harris Haematoxylin, 168 
dehydrated through an ascending series of alcohols and mounted using DPX, coverslipped 169 
and images were captured under an Olympus BX60 microscope (Olympus, Essex, UK). 170 
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Semi-quantitative analysis of immunostaining by HSCORE 171 
The intensity of immunoreactivity for each antibody was assessed in cellular compartments 172 
within sections by a four-point semi-quantitative scoring system as follows: negative (0), weak 173 
(1), moderate (2) and strong (3).  The H-score manual method of visual analysis is a double 174 
graded system in which the total sum of a graded average intensity score is multiplied by the 175 
percentage area expression.  This obtains a score range from 0 to 300 by multiplying the 176 
intensity of the stains (score 0-3) and the percentage of area stained (0-100) as previously 177 
described (Ponglowhapan et al. 2008).  Intensity of staining was considered separately in 178 
endometrial compartments in luminal epithelium, glands, stromal cells and vasculature.  179 
Percentage expression reflects the percentage area immuno-stained in each layer.  The 180 
estimate was based on ten random fields per section from all the animals in each treatment 181 
group.  The images were scored by two independent experienced assessors blinded to the 182 
corresponding experimental groups under scoring.  Data were analysed from a minimum of 183 
at least three animals per experimental group using Graphpad Prism one-way analysis of 184 
variance test with post hoc Tukey’s test for multiple comparisons. P<0.05 was considered to 185 
indicate a statistically significant difference. 186 
 
Results 187 
Plasma oestradiol and progesterone concentrations 188 
At the time of uteri sample collection, plasma progesterone levels were higher in luteal phase 189 
animals (2.3 ± 0.49 ng/ml) in comparison to follicular phase ewes (below detection levels of 190 
the assay; < 0.05 ng/ml).  Progesterone was non-detectable in the OVX group, but significantly 191 
increased in both OVX P and OVX EP groups in response to progesterone (P4) or estradiol + 192 
progesterone (E2+P4) treatment respectively (Fig. 1A).  Plasma oestradiol levels at sample 193 
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collection from follicular phase ewes were 6.1 ± 1.69 pg/ml (Fig. 1B).  In both OVX and OVX P 194 
ewes, oestradiol levels were below assay detection levels, whereas in OVX EP animals, 195 
oestradiol levels began a steady increase following injections administered daily for 3 196 
consecutive days, and continued to increase until day 10 of sample collection. 197 
Effects of oestrous cycle on protein expression of VEGF in the ovine endometrium  198 
Protein expression of VEGFA/R1/2, Ang-1/2 and TIE2 was examined by 199 
immunohistochemistry and semi-quantified using HSCORE method.  For each protein 200 
analysed, variation in the intensities of immunostaining detected in the cytoplasm of all 201 
cellular layers of the endometrium studied is summarised in Table 1.  VEGFA immunostaining 202 
was evident in all cellular layers examined in the endometrium in follicular and luteal phases 203 
(Fig. 2A and B).  The non-vascular cells of the epithelium stained strongest for VEGFA as 204 
compared to vascular cells in both follicular and luteal phases.  VEGFA protein was localised 205 
to the cytoplasm of both luminal epithelium (LE) and was more strongly evident in glandular 206 
epithelium (GE) of the upper zone.  No significant differences were detected for VEGFA in 207 
luminal and glandular epithelium between cycle phases (P>0.05).  VEGFA staining in the 208 
stromal compartment was not cycle-dependant, with low level HSCORE values exhibited in 209 
both follicular and luteal phases.  In the vasculature, VEGFA levels were shown to be cycle-210 
dependant with stronger staining intensity in the endothelial cells in follicular phase sections, 211 
compared to the luteal phase (P<0.05). Positive VEGFA staining was observed in both vascular 212 
endothelial cells and smooth muscle cells surrounding blood vessels (BV), arterioles and 213 
capillaries.   214 
Effects of ovarian steroids on protein expression of VEGFA in the ovine endometrium  215 
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Overall, in OVX sections due to a loss of ovarian steroids as a result of ovariectomy, the depth 216 
of the luminal epithelium and the diameter of uterine glands were markedly reduced 217 
compared to OVX EP/P tissues.  In OVX tissue, there was a lack of positive VEGFA 218 
immunostaining to almost undetectable levels (Fig.2E).  Treatment with the ovarian steroids 219 
induced a significant up-regulation of VEGFA protein, in the luminal and glandular epithelium, 220 
and in vascular cells (P<0.05; Fig. 2H).  Steroid-treated OVXP (Fig. 2D) and OVXEP ewes 221 
exhibited significantly increased HSCORE values for VEGF compared to OVX tissue.  Combined 222 
OVXEP treatment produced the greatest up-regulation of VEGF in all cell types examined, 223 
above that of progesterone alone (P<0.05; Fig. 2C). 224 
Effects of oestrous cycle on protein expression of VEGFR1 and 2 in the ovine endometrium  225 
VEGFR1 exhibited a staining distribution pattern comparable to that of VEGFA.  Cells of the 226 
luminal and glandular epithelium in the superficial endometrium were most strongly stained 227 
for VEGFR1 with no significant differences observed between follicular and luteal phases (Fig. 228 
3A and B).  In the vasculature, VEGFR1 stained stronger in follicular phase, evident in both 229 
endothelial cells and smooth muscle cells of capillaries, and arterioles, although there was no 230 
significant effect compared to luteal ewes (Fig. 3A and B).  Overall staining indices for VEGFR2 231 
were relatively lower than VEGFR1 in the endometrium, reflected by an approximate 2-fold 232 
higher HSCORE value for VEGFR1 than VEGFR2 in luminal and glandular epithelium and 233 
vascular cells (Fig. 3G and 4G).  Cell specific oestrus cycle-dependent differences in VEGFR2 234 
expression were detected.  In luteal phase, VEGFR2 was significantly higher in luminal 235 
epithelium compared to follicular phase, but not in the glands and stroma (P<0.05; Fig. 4A and 236 
4B).  In the vasculature, VEGFR2 was predominantly localised to the endothelial cells of blood 237 
vessels, with significantly stronger levels in the follicular phase (P<0.05).  Only a small number 238 
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of cells in the stromal compartment stained positively for VEGFR2 from follicular and luteal 239 
animals. 240 
Effects of ovarian steroids on protein expression of VEGFR1 and 2 in the ovine endometrium  241 
Treatment with the ovarian steroids (OVXP/EP) induced a significant increase in both VEGFR1 242 
and VEGFR2 compared to OVX ewes in all epithelial and vascular cells but not in the stroma 243 
(Figs. 3H and 4H).  The effects of combined OVXEP treatment induced the strongest intensity 244 
staining for VEGFR1 in luminal and glandular epithelium, comparable to HSCORE values in 245 
vascular cells (Fig. 3C).  Progesterone treatment alone induced an increase in VEGFR1 in all 246 
cell types examined, however this was not a significant effect (Fig. 3D).  VEGFR2 247 
immunoreactive protein was also induced in uterine sections in response to the ovarian 248 
steroids (Fig. 4H).  Combined OVXEP treatment produced the most marked increase in 249 
VEGFR2 in both luminal and glandular epithelium, and most significantly in vascular 250 
endothelial cells (Fig. 4C; P<0.001).  VEGFR2 immunoreaction intensity was weaker along the 251 
luminal epithelium and in glands and vascular cells in response to progesterone alone (Fig. 252 
4D). 253 
Effects of oestrous cycle on protein expression of angiopoietins in the ovine endometrium  254 
Ang-1 and Ang-2 proteins were both expressed in a cycle dependent manner and were 255 
detected in all cellular layers examined at varying intensities (Figs. 5A, B and 6A, B).  In the 256 
blood vessels, Ang-1 is strongly evident in the supportive smooth muscle cells and in 257 
endothelial cells.  Ang-1 is also detected in non-vascular luminal and glandular epithelium and 258 
in stroma.  Ang-1 immunostaining was significantly reduced in follicular phase compared to 259 
luteal phase in epithelial cells and blood vessels.  In luteal phase, Ang-1 is significantly 260 
increased in luminal epithelia, superficial glands and the vasculature, but not stroma (P<0.05; 261 
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Fig. 5B). Ang-2 protein exhibited a similar spatial distribution in uterine sections to Ang-1 (Fig 262 
6A).  Ang-2 protein was detected in the luminal epithelium, and stained stronger in glands of 263 
the superficial endometrium.  Ang-2 was strongly evident in smooth muscle cells of the 264 
vasculature and in endothelial cells.  Immunostaining for Ang-2 was consistently higher in 265 
luteal phase animals in all cells examined except the stroma (P<0.05; Fig. 6B). 266 
Effects of ovarian steroids on protein expression of the angiopoietins in the ovine 267 
endometrium  268 
Both ANG1 and ANG2 protein exhibited an increase in response to steroid treatments 269 
compared to OVX tissue (Fig. 5 and 6).  Overall, Ang-1 and 2 were distinct and significantly 270 
higher (P<0.05) in all three cellular layers, although less elevated in the stroma, in response 271 
to progesterone treatment (Fig. 5D and 6D).  Ang-1 and Ang-2 immunostaining was weak in 272 
response to combined OVXEP treatment, and did not induce a significant effect in comparison 273 
to OVX tissues, reflected by HSCORE values approximately 4-fold lower than for progesterone 274 
alone (Fig. 5C and 6C). 275 
TIE-2 protein was strongly associated with blood vessels in both follicular and luteal phases, 276 
with strong staining localised to both endothelial and smooth muscle cells of capillaries, 277 
arterioles and venules (Fig. 7A and 7B).  TIE-2 immunoreactivity was highly detectable in the 278 
superficial glands, in follicular phase and most significantly in luteal phase.  TIE-2 staining was 279 
undetectable in cells of the luminal epithelium in the luteal phase (Fig. 7B), and almost at 280 
undetectable levels in follicular phase (Fig. 7A).  TIE-2 was up-regulated in response to both 281 
progesterone and combined oestradiol and progesterone treatments, in cells of the 282 
vasculature (P<0.0001) and in the superficial glands (P<0.0001).  283 
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Discussion 284 
In the present study, VEGFA protein and receptors were demonstrated by 285 
immunohistochemistry in the ovine endometrium, which have cycle-dependent variations in 286 
specific cell types and in response to the ovarian steroids.  The main findings of our study 287 
demonstrated that epithelial, stromal and vascular cells produce VEGFA, and 288 
immunoreactivity in the vasculature was highest in the follicular phase.  VEGF receptors were 289 
expressed by ECs of blood vessels, and specifically VEGFR2 vascular expression was highest in 290 
the follicular phase. VEGFR1 and VEGFR2 immunostaining was also present in the epithelial 291 
and stromal cells of the superficial endometrium. The distinct period of elevated VEGFA 292 
vascular expression in the follicular phase is in accordance with findings of (Punyadeera et al. 293 
2006) who demonstrated increased VEGF expression in early proliferative human 294 
endometrium, and (Maas et al. 2001) who observed that early-proliferative phase 295 
endometrium has higher angiogenic activity than late proliferative phase.   296 
The present study also described that in our ovariectomised model, the influence of 297 
oestradiol and progesterone induced high VEGFA expression in epithelial and vascular cells. 298 
Although oestradiol injections were administered only on days 1-3 of treatments, followed by 299 
progesterone thereafter, circulating levels of plasma oestradiol remained high until the final 300 
day 10 of treatment.  It is likely that this results from a delay in absorption of oestradiol from 301 
the muscle at the site of injection.  Thus, high circulating levels of oestradiol were maintained 302 
and endometrial samples were influenced by oestradiol until the day of sample collection.  303 
This is an important point to consider when interpreting data from this study. 304 
Previous studies have shown that VEGF mediates processes of angiogenesis, vascular 305 
permeability and endothelial cell proliferation via VEGFR2.  The highest expression of VEGFR2 306 
in vascular cells shown in the follicular phase in this study may be indicative of the 307 
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requirement for VEGFR2-VEGFA mediated mitogenic activity of endothelial cells, during a 308 
period characterised by accelerated vascular growth. Further studies are required in the ovine 309 
endometrium, to determine the functionality of VEGFA in specific phases of the oestrus cycle. 310 
In accordance with previous studies in primates (Rowe et al. 2003), cattle (Sagsoz and Saruhan 311 
2011) and in humans (Charnock-Jones et al. 1993), VEGFA immunostaining was stronger in 312 
luminal and glandular epithelial cells than in ECs.  Endometrial epithelial and stromal cell 313 
proliferation and differentiation are controlled by the actions of oestradiol and progesterone, 314 
mediated by several growth factors, including VEGFA (Gabler et al. 1999).  In this study, the 315 
marked increase in VEGFA expression induced in epithelial cells by combined oestradiol and 316 
progesterone treatment, suggests oestradiol regulation of VEGFA in these cell types, which 317 
may act to promote endometrial growth.  Although no significant differences in VEGFA 318 
expression were observed across cycle phases in epithelial cells, a trend towards stronger 319 
staining in both glandular and luminal epithelial cells in mid-luteal phase was notable. In 320 
bovine uterus (Sagsoz and Saruhan 2011) reported a stronger VEGF signal in luminal and 321 
glandular epithelium in luteal phase, but no significant differences were detected in stromal 322 
or smooth muscle cells.  (Tasaki et al. 2010) showed that VEGF mRNA was highest at estrus 323 
and VEGF protein peaked at early luteal phase in bovine endometrium.  The significance of 324 
VEGF in these cells types at this time may be required in stimulating the increase in secretory 325 
activity of epithelial cells during the luteal phase.  326 
VEGFR1 and VEGFR2 were highly localised to ECs of blood vessels, and are known to mediate 327 
VEGF signalling in the endometrium.  VEGFR2 expression was cycle-dependant, highest in 328 
follicular phase, and stimulated by oestradiol treatment.  This is indicative of oestradiol 329 
regulation of VEGFR2 in endothelial cells during the oestradiol-dominant follicular phase of 330 
the oestrous cycle.  VEGFR1 did not change significantly between the follicular phase and 331 
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luteal phase, although overall VEGFR1 levels were higher in all cell types examined than 332 
VEGFR2. Given the higher binding affinity of VEGF for VEGFR1, this suggests a significant role 333 
for VEGFR1-VEGF mediated signalling.  Similar to VEGFR2, VEGFR1 immunoreactivity was high 334 
in ECs in blood vessels in the superficial endometrium, and was upregulated in epithelial and 335 
vascular cells in response to oestradiol.  Since VEGF is secreted by epithelial and stromal cells, 336 
a paracrine mechanism is likely, with VEGF binding to receptors on endothelial cells to 337 
stimulate different angiogenic functions. Although VEGF signalling via VEGFR1 cannot 338 
mediate endothelial cell proliferation, it has been implicated to facilitate vascular 339 
permeability and endothelial cell migration (Meduri et al. 2000).   Intense immunostaining 340 
was detected in the ECs of blood vessels in follicular phase and was still highly detectable in 341 
mid-luteal phase endometrium.  During this cycle phase, the characteristic changes associated 342 
with angiogenesis include vessel hyperpermeability and rapid expansion of the vascular bed 343 
towards the base of the epithelium in preparation for blastocyst attachment.   344 
The functions of the angiopoietins in the endometrium and during implantation are not well 345 
understood.  In this study, it was demonstrated that Ang-1 was high during the luteal phase, 346 
and that progesterone induced a ~5-fold increase in epithelial and vascular cells. In a primate 347 
model, during induced menstrual cycles in rhesus macaques, progesterone withdrawal in the 348 
early secretory phase induced a decline in Ang-1 mRNA in the glands and vascular smooth 349 
muscle cells in the endometrium (Nayak et al. 2005).  The progesterone-dominant luteal 350 
phase is associated with processes of vascular maturation, characterised by increased 351 
interactions between endothelial cells and supportive smooth muscle cells.  Ang-1 is the 352 
primary agonist for TIE-2 receptors, and functions via paracrine signalling, to bind and 353 
phosphorylate TIE-2, thereby promoting associations between vascular cell types, to maintain 354 
blood vessel stability (Woolf et al. 2009). Ang-1 was localised to smooth muscle cells of blood 355 
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vessels, highly expressed in the luteal phase.  Our data shows TIE-2 immunoreactivity is largely 356 
restricted to ECs of blood vessels, with no significant differences between cycle phases.  As 357 
Ang-1 is a secretory glycoprotein, and we show Ang-1 expression by epithelial and vascular 358 
cells in the superficial endometrium, whereas its receptor, TIE-2 is expressed by ECs, we 359 
suggest Ang-1 may stimulate processes of increased vascular stability in a paracrine fashion. 360 
Ang-1 is shown to function by paracrine signalling in other tissue types, including glomeruli of 361 
the kidney, where Ang-1 is expressed by podocytes and upregulates TIE-2 receptors on 362 
endothelial cells of capillaries (Woolf et al. 2009). 363 
Similarly, Ang-2 peaked in the luteal phase and was stimulated in response to progesterone.  364 
 Ang-2 antagonises Ang-1 binding to TIE2 and does not induce signal transduction.  In doing 365 
so, Ang-2 can disrupt the associations between endothelial cells and peri-vascular support 366 
cells, to promote apoptosis and vessel regression (Woolf et al. 2008).  Such processes may be 367 
advantageous during early gestation when placentation requires remodelling of an existing 368 
vascular network and formation of new branching vessels (Kappou et al. 2014).  Pro-369 
angiogenic effects of Ang-2 are thought to be dependent on available local VEGF expression.  370 
It has been indicated that Ang-2 may promote the accessibility of ECs to VEGF, thereby 371 
promoting neovascularisation.  Notably, a previous study in an OVX-ewe model, reported that 372 
oestradiol-induced up-regulation of Ang-1/2 and TIE-2, occurred at 2 h post-treatment 373 
(Johnson et al. 2006). In fact this response time was shorter than the oestradiol-induced up-374 
regulation of VEGF, observed at 4 h. In the present study, the effects of oestradiol were also 375 
stimulatory on angiopoeitin expression, however progesterone alone exhibited a greater 376 
response. Of interest, would be to compare progesterone treatment in the aforementioned 377 
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groups OVX-ovine model. However, differences in results between studies may be due to 378 
analysis at the protein level, in the present study, and at the mRNA level in the previous study.  379 
 
Although no staining was evident in the luminal epithelium or stromal cells, TIE-2 was 380 
unexpectedly evident in glandular epithelium.  Analysis of these results should be approached 381 
with some degree of caution, given that TIE-2 is an endothelial specific marker.  Possibly, there 382 
is a lack of specificity of the polyclonal antibody used, which could prove a limitation of this 383 
study. However, there is some previous evidence of non-vascular TIE-2 expression in epithelial 384 
cells and a distinct population of monocytes (Coffelt et al. 2010). Future endometrium- 385 
specific studies of TIE-2 expression are required to discern these possibilities.  386 
It is noteworthy to highlight the limitations of this study, in which antibodies with higher 387 
specificity may have been selected, and a more state of the art software analysis could have 388 
greater benefit. However, it is also critical to highlight that there is very limited evidence for 389 
angiogenic factors in the sheep. Although many other species have been studied in this area, 390 
this study provides novel data, which is no doubt crucial, and may highlight species-specific 391 
differences in implantation and placentation, that would subsequently be reflected in 392 
differences in angiogenic factor expression. Studies in ruminant species of economic 393 
relevance like sheep are critical, as evidence is limited on VEGF in cyclic ovine endometrium 394 
but has only been demonstrated in pregnant uterus (Grazul-Bilska et al. 2010).  Early 395 
embryonic loss is a limiting factor which compromises reproduction, reflected in the fact that 396 
high fertilisation rates (70-80%) do not necessarily equate to similar pregnancy rates (Bridges 397 
et al. 2013).  Deficient development and/or function of the vasculature may be a contributing 398 
factor to such early pregnancy loss.    399 
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In conclusion, this study provides evidence that VEGF and receptors VEGFR1/2 are expressed 400 
by uterine epithelial, vascular and stromal cells in the ovine endometrium, in a cycle-401 
dependant manner, predominantly induced by oestradiol. The angiopoietin system is 402 
dominant in the luteal phase, and regulated by progesterone may be involved in processes of 403 
vessel integrity and stabilisation of a newly formed maternal vascular system.   404 
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(ix) Table 1: Synopsis of results  547 
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Staining intensity:  +++ = strong, ++ = medium, + = weak, -no staining  548 
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 (x) Figure Legends: 549 
Figure 1: Plasma concentrations of progesterone (A) and oestraidol (B) in ovariectomised 550 
ewes, treated with corn oil (vehicle) (OVX; n=6), or progesterone (OVX P; n=9) or oestradiol + 551 
progesterone (OVX EP; n=8). Values represent mean values ± SEM. 552 
Figure 2:  Immunohistochemical localisation and quantification of VEGF in ovine 553 
endometrium. VEGF in the follicular and luteal phases (A, B) of the oestrous cycle, and 554 
ovariectomised ewes treated with oestradiol and progesterone (OVXEP; C), progesterone 555 
(OVXP; D), or vehicle (OVX; E). Immunostaining with isotype antibody for negative control (F). 556 
VEGF is visualised as brown staining (DAB) and nuclei are counterstained with hematoxylin. 557 
HSCORE values represent mean ± SEM (G, H). *significance (P< 0.05; n=3). LE; luminal 558 
epithelium, GE; glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 559 
Figure 3:  Immunohistochemical localisation and quantification of VEGFR1 in ovine 560 
endometrium. VEGFR1 in the follicular and luteal phases (A, B) of the oestrous cycle, and 561 
ovariectomised ewes treated with oestradiol and progesterone (OVXEP; C), progesterone 562 
(OVXP; D), or vehicle (OVX; E). Immunostaining with isotype antibody for negative control (F). 563 
VEGFR1 is visualised as brown staining (DAB) and nuclei are counterstained with hematoxylin. 564 
HSCORE values represent mean ± SEM (G, H). *significance (P< 0.05; n=3). LE; luminal 565 
epithelium, GE; glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 566 
Figure 4:  Immunohistochemical localisation and quantification of VEGFR2 in ovine 567 
endometrium. VEGFR2 in the follicular and luteal phases (A, B) of the oestrous cycle, and 568 
ovariectomised ewes treated with oestradiol and progesterone (OVXEP; C), progesterone 569 
(OVXP; D), or vehicle (OVX; E). Immunostaining with isotype antibody for negative control (F). 570 
VEGFR2 is visualised as brown staining (DAB) and nuclei are counterstained with hematoxylin. 571 
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HSCORE values represent mean ± SEM (G, H). *significance (P< 0.05; n=3). LE; luminal 572 
epithelium, GE; glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 573 
Figure 5:  Immunohistochemical localisation and quantification of Ang-1 in ovine 574 
endometrium. Ang-1 in the follicular and luteal phases (A, B) of the oestrous cycle, and 575 
ovariectomised ewes treated with oestradiol and progesterone (OVXEP; C), progesterone 576 
(OVXP; D), or vehicle (OVX; E). Immunostaining with isotype antibody for negative control (F). 577 
Ang-1 is visualised as brown staining (DAB) and nuclei are counterstained with hematoxylin. 578 
HSCORE values represent mean ± SEM (G, H). *significance (P< 0.05; n=3). LE; luminal 579 
epithelium, GE; glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 580 
Figure 6:  Immunohistochemical localisation and quantification of Ang-2 in ovine 581 
endometrium. Ang-2 in the follicular and luteal phases (A, B) of the oestrous cycle, and 582 
ovariectomised ewes treated with oestradiol and progesterone (OVXEP; C), progesterone 583 
(OVXP; D), or vehicle (OVX; E). Immunostaining with isotype antibody for negative control (F). 584 
Ang-2 is visualised as brown staining (DAB) and nuclei are counterstained with hematoxylin. 585 
HSCORE values represent mean ± SEM (G, H). *significance (P< 0.05; n=3). LE; luminal 586 
epithelium, GE; glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 587 
Figure 7:  Immunohistochemical localisation of TIE-2 in ovine endometrium. TIE-2 in the 588 
follicular and luteal phases (A, B) of the oestrous cycle, and ovariectomised ewes treated with 589 
oestradiol and progesterone (OVXEP; C), progesterone (OVXP; D), or vehicle (OVX; E). 590 
Immunostaining with isotype antibody for negative control (F). TIE-2 is visualised as brown 591 
staining (DAB) and nuclei are counterstained with hematoxylin. HSCORE values represent 592 
mean ± SEM (G, H). Significance (*P< 0.05, ***P< 0.0001; n=3). LE; luminal epithelium, GE; 593 
glandular epithelium, BV; blood vessel, ST; stroma. Scalebar: 50 μm. 594 
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